Get started
Author

Ioannis F. Voutsas

Observed names: I F Voutsas, I.F. Voutsas, IOANNIS F VOUTSAS, Ioannis F Voutsas, Ioannis Voutsas, Ioannis F. Voutsas, Voutsas, Ioannis
Institution: St Savas Hospital
ORCID: 0000-0003-2696-2200
Observed ORCID: 0000-0003-2696-2200
OpenAlex ID: A5057175485
Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor
2000 · Constantin N Baxevanis, Ioannis F Voutsas, et al. · The Journal of Immunology · 161
PDF
Compromised anti-tumor responses in tumor necrosis factor-α knockout mice
2000 · Constantin N. Baxevanis, Ioannis F. Voutsas, et al. · European Journal of Immunology · 86
PDF
New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
2014 · Spiros Vlahopoulos, Elena Critselis, et al. · Current Drug Targets · 61
Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
2006 · Nectaria N. Sotiriadou, Nikoletta L. Kallinteris, et al. · Cancer Immunology Immunotherapy · 53
HER-2/neu as a Target for Cancer Vaccines
2010 · Constantin N Baxevanis, Ioannis F Voutsas, et al. · Immunotherapy · 49
Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain
2007 · Ioannis F. Voutsas, Angelos D. Gritzapis, et al. · International Journal of Cancer · 48
Toll-Like Receptor Agonists: Current Status and Future Perspective on their Utility as Adjuvants in Improving Antic Ancer Vaccination Strategies
2013 · Constantin N Baxevanis, Ioannis F Voutsas, et al. · Immunotherapy · 43
Prothymosin Alpha: An Alarmin and More...
2017 · Pinelopi Samara, Chrysoula-Evangelia Karachaliou, et al. · Current Medicinal Chemistry · 36
Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/ neu with Potent Antitumor Properties
2008 · Angelos D Gritzapis, Ioannis F Voutsas, et al. · The Journal of Immunology · 35
PDF
Mistletoe Lectin I-Induced Effects on Human Cytotoxic Lymphocytes. I. Synergism with Il-2 in the Induction of Enhanced Lak Cytotoxicity
1998 · Constantin N. Baxevanis, Ioannis F. Voutsas, et al. · Immunopharmacology and Immunotoxicology · 30
The immunologically active site of prothymosin α is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients
2006 · Margarita Skopeliti, Ioannis F. Voutsas, et al. · Cancer Immunology Immunotherapy · 29
The prognostic value of alpha-thymosins in breast cancer.
1998 · O E Tsitsilonis, E Bekris, et al. · PubMed · 29
Peptide Vaccination Breaks Tolerance to HER-2/ neu by Generating Vaccine-Specific FasL+ CD4+ T Cells: First Evidence for Intratumor Apoptotic Regulatory T Cells
2010 · Angelos D. Gritzapis, Ioannis F. Voutsas, et al. · Cancer Research · 28
Synergy between interleukin-2 and prothymosin ? for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas
2000 · Ioannis F. Voutsas, Constantin N. Baxevanis, et al. · Cancer Immunology Immunotherapy · 21
Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia
2022 · Garrett M. Dancik, Ioannis F. Voutsas, et al. · Molecular Biology Reports · 19
PDF
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
2015 · Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, et al. · Cancer Immunology Immunotherapy · 19
PDF
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+T-cells
2016 · Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, et al. · OncoImmunology · 18
PDF
Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model
2017 · Sotirios P. Fortis, Louisa G. Mahaira, et al. · Cancer Immunology Immunotherapy · 17
Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α
1999 · Constantin N. Baxevanis, Gregory Spanakos, et al. · Cancer Immunology Immunotherapy · 17
Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients
2010 · Nikolaos Tsavaris, Ioannis F. Voutsas, et al. · Investigational New Drugs · 16
T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker
2022 · Constantin N. Baxevanis, Angelos D. Gritzapis, et al. · Cancers · 15
PDF
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
2016 · Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
2011 · Angelos D. Gritzapis, Ioannis F. Voutsas, et al. · Cancer Immunology Immunotherapy · 14
Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer
2013 · Ioannis D. Xynos, Maria L. Karadima, et al. · Oncology · 13
Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice
2012 · Ioannis F. Voutsas, Nikolaos Pistamaltzian, et al. · European Journal of Cancer · 13
Works count: 54
Citation count: 969
H-index: 17
I10-index: 28
Year
Topic
Type